Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00683917 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids
A Phase 2 study, sponsored by Repros Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00683917 is a Phase 2 study that was terminated before completion, run by Repros Therapeutics. The registered enrollment target is 10 participants.
The verdict
NCT00683917, a Phase 2 study, was terminated before completion, sponsored by Repros Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
PK of 25 mg and 50 mg Proellex® administered once daily (QD) over a 4-month period.
Interventions
- DRUG Lupron Depot
- DRUG Proellex 25 mg
- DRUG Proellex 50 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00683917
The ClinicalTrials.gov registry entry for NCT00683917 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repros Therapeutics, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lupron Depot is the first listed.
NCT00683917 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00683917 about?
NCT00683917 is a clinical study titled "Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids". PK of 25 mg and 50 mg Proellex® administered once daily (QD) over a 4-month period.
What is the current status of trial NCT00683917?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2008-05. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00683917?
The interventions under investigation include: Lupron Depot (DRUG), Proellex 25 mg (DRUG), Proellex 50 mg (DRUG).
Who is sponsoring clinical trial NCT00683917?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.